Vitamin K-2 by NewtonEverett — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size

120 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K-2

50 mcg (63% DV)

✅ Within RDA (0.4× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.05mg

Other Ingredients

Sunflower seed Oil Gelatin Vegetable Glycerin Contains Less Than 2% of

Label Claims — Verification

❓ All Other

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Sugar Free

Product Information

📋 Directions for Use

Directions: For adults, take one (1) softgel daily, preferably with a meal.

⚠️ Warnings & Precautions

Warning: If you are pregnant, nursing or taking any medications, consult your doctor before use.

Discontinue use and consult your doctor if any adverse reactions occur

KEEP OUT OF REACH OF CHILDREN.

Not suitable for vegetarians.

Contains soy ingredients.

🧪 Formulation Notes

No artificial flavor or sweetener, preservatives, sugar, starch, milk, lactose, gluten, wheat, yeast or shellfish. Sodium free.

Contains soy ingredients.

Additional Information

Pure - Potent - Bioavailable We are driven to deliver highly potent, ultra-pure nutritional products with uncompromised quality. Our premium-grade liquid softgels are designed to provide an ideal delivery vehicle for maximum absorption and enhanced bioavailability.

Store at room temperature.

newtoneverett(R)

Made in USA

Product Details

UPC / SKU 6 89076 03145 5

DSLD Entry Date 2014-06-25

Product Type Vitamin

Form Softgel Capsule

Brand NewtonEverett

DSLD ID 34784

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation